NetScientific said portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB) (Nasdaq: PDSB), has released presentations of clinical data from two Phase 2 clinical trials of HPV-positive cancer treatment PDS0101.
The presentations will be made at the 37th Annual Meeting of the Society for Immunotherapy of Cancer being held from 8 to 12 November 2022 in the United States.
Frank Bedu-Addo, PDS Biotech’s CEO, said that: "Taken together, the data being presented demonstrate the potential ability of PDS0101 to elicit in patients the right type and quality of therapeutic immune response.
“This seems to allow PDS0101 to work in combination with a variety of therapeutic agents to generate clinical responses that appear to exceed current standards of care and allow for improved outcomes in patients with HPV-positive cancers.”
Ilian Iliev, NetScientific’s chief executive, added: "These presentations set out remarkable progress in the fight against HPV-positive cancers, and PDS Biotech should be enormously proud of their achievements